Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norditropin SimpleXx on Bone Mineral Density in Young Adults
NCT00184678Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2002
- Primary completion
- Jul 2006
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of somatropin in adult growth hormone deficiency (AGHD) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Bone Mineral Density at 2 years. Started Feb 2002; status: completed.
02
Drugs
somatropin
03
Conditions
adult growth hormone deficiency (AGHD)
Beyond the preview
Go deeper on NCT00184678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00184678.